. .. Population-et-methode,

.. .. Caractéristique-de-la-population,

. .. Méthodologie,

. .. Analyses-statistiques,

R. .. ,

. .. Efficacité-du-rituximab,

. .. Tolérance-du-rituximab,

D. :. ,

. .. Bibliographie,

, Bibliographie 1. Compston A, Coles A. Multiple sclerosis, Lancet Lond Engl, vol.372, issue.9648, pp.1502-1519, 2008.

F. D. Lublin, M. Baier, and G. Cutter, Effect of relapses on development of residual deficit in multiple sclerosis, Neurology. 9 déc, vol.61, issue.11, pp.1528-1560, 2003.

P. S. Sørensen, Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis, J Neurol Sci. déc, vol.311, issue.1, pp.29-34, 2011.

C. Hirst, G. Ingram, O. Pearson, T. Pickersgill, N. Scolding et al., Contribution of relapses to disability in multiple sclerosis, J Neurol. févr, vol.255, issue.2, pp.280-287, 2008.

C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, issue.20, pp.1430-1438, 2000.

S. Menon, A. Shirani, Y. Zhao, J. Oger, A. Traboulsee et al., Characterising aggressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.84, issue.11, pp.1192-1200, 2013.

L. Page, E. Leray, E. Taurin, G. Coustans, M. Chaperon et al., Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry. janv, vol.79, issue.1, pp.52-58, 2008.

E. Cocco, P. Marchi, C. Sardu, P. Russo, A. Paolillo et al., Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. sept, vol.13, issue.8, pp.975-80, 2007.

F. Esposito, M. Radaelli, V. Martinelli, M. P. Sormani, M. Boneschi et al., Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. déc, vol.16, issue.12, pp.1490-1499, 2010.

G. Edan, G. Comi, L. Page, E. Leray, E. Rocca et al., Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial, J Neurol Neurosurg Psychiatry. déc, vol.82, issue.12, pp.1344-50, 2011.

G. Filippini, D. Giovane, C. Vacchi, L. , D. 'amico et al., Immunomodulators and immunosuppressants for multiple sclerosis: a network metaanalysis. In: The Cochrane Collaboration, éditeur. Cochrane Database of Systematic Reviews

U. K. Chichester, , 2013.

. Disponible,

I. Tramacere, D. Giovane, C. Salanti, G. , D. 'amico et al., Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. In: The Cochrane Collaboration, éditeur. Cochrane Database of Systematic Reviews

U. K. Chichester, , 2015.

L. Kappos, E. Radue, O. 'connor, P. Polman, C. Hohlfeld et al., A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.387-401, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617764

L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'connor et al., Oral fingolimod (FTY720) for relapsing multiple sclerosis, N Engl J Med, vol.355, issue.11, pp.1124-1140, 2006.

T. Saida, S. Kikuchi, Y. Itoyama, Q. Hao, T. Kurosawa et al., A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis, Mult Scler J. sept, vol.18, issue.9, pp.1269-77, 2012.

P. A. Calabresi, E. Radue, D. Goodin, D. Jeffery, K. W. Rammohan et al., Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, Lancet Neurol. juin, vol.13, issue.6, pp.545-56, 2014.

J. A. Cohen, F. Barkhof, G. Comi, H. Hartung, B. O. Khatri et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-415, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617750

R. Nixon, N. Bergvall, D. Tomic, N. Sfikas, G. Cutter et al., No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis, Adv Ther, vol.31, issue.11, pp.1134-54, 2014.

P. Iaffaldano, G. Lucisano, C. Pozzilli, B. Morra, V. Ghezzi et al., Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis, Brain, vol.138, issue.11, pp.3275-86, 2015.

L. Mantia, L. Tramacere, I. Firwana, B. Pacchetti, I. Palumbo et al., Fingolimod for relapsing-remitting multiple sclerosis, The Cochrane Collaboration, éditeur. Cochrane Database of Systematic Reviews

U. K. Chichester, , 2016.

C. H. Polman, P. W. O'connor, E. Havrdova, M. Hutchinson, L. Kappos et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.899-910, 2006.

R. A. Rudick, W. H. Stuart, P. A. Calabresi, C. Confavreux, S. L. Galetta et al., Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.911-923, 2006.

A. D. Goodman, H. Rossman, A. Bar-or, A. Miller, D. H. Miller et al., GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study, Neurology. 3 mars, vol.72, issue.9, pp.806-818, 2009.

M. Hutchinson, L. Kappos, P. A. Calabresi, C. Confavreux, G. Giovannoni et al., The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL, J Neurol. mars, vol.256, issue.3, pp.405-420, 2009.

B. Oliver-martos, T. Órpez-zafra, P. Urbaneja, R. Maldonado-sanchez, L. Leyva et al., Early development of anti-natalizumab antibodies in MS patients, J Neurol. sept, vol.260, issue.9, pp.2343-2350, 2013.

D. B. Clifford, Progressive Multifocal Leukoencephalopathy Therapy. J Neurovirol. déc, vol.21, issue.6, pp.632-638, 2015.

T. Kalincik, D. Horakova, T. Spelman, V. Jokubaitis, M. Trojano et al., Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis, Ann Neurol. mars, vol.77, issue.3, pp.425-460, 2015.

L. Barbin, C. Rousseau, N. Jousset, R. Casey, M. Debouverie et al., Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study, Neurology. 23 févr, vol.86, issue.8, pp.771-779, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01299977

D. S. Goodin, E. M. Frohman, G. P. Garmany, J. Halper, W. H. Likosky et al., Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology. 22 janv, vol.58, issue.2, pp.169-78, 2002.

L. J. Scott and D. P. Figgitt, Mitoxantrone: a review of its use in multiple sclerosis, CNS Drugs, vol.18, issue.6, pp.379-96, 2004.

G. Edan, D. Miller, M. Clanet, C. Confavreux, O. Lyon-caen et al., Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry. févr, vol.62, issue.2, pp.112-120, 1997.

E. Millefiorini, C. Gasperini, C. Pozzilli, D. 'andrea, F. Bastianello et al., Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome, J Neurol. mars, vol.244, issue.3, pp.153-162, 1997.

A. J. Coles, D. Compston, K. W. Selmaj, S. L. Lake, and S. Moran, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, CAMMS223 Trial Investigators, vol.359, pp.1786-801, 2008.

J. A. Cohen, A. J. Coles, D. L. Arnold, C. Confavreux, E. J. Fox et al., Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, vol.380, pp.1819-1847, 2012.

A. J. Coles, C. L. Twyman, D. L. Arnold, J. A. Cohen, C. Confavreux et al., Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet, vol.380, pp.1829-1868, 2012.

A. J. Coles, E. Fox, A. Vladic, S. K. Gazda, V. Brinar et al., Alemtuzumab more effective than interferon ?-1a at 5-year follow-up of CAMMS223 clinical trial, Neurology. 3 avr, vol.78, issue.14, pp.1069-78, 2012.

A. J. Coles, Alemtuzumab therapy for multiple sclerosis, Neurother J Am Soc Exp Neurother. janv, vol.10, issue.1, pp.29-33, 2013.
DOI : 10.1007/s13311-012-0159-0

URL : http://europepmc.org/articles/pmc3557360?pdf=render

H. Haute, Autorité de Santé-LEMTRADA (alemtuzumab), immunosuppresseur sélectif, p.22, 2017.

G. Comi, S. D. Cook, G. Giovannoni, K. Rammohan, P. Rieckmann et al., MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study, J Neurol. avr, vol.260, issue.4, pp.1136-1182, 2013.

T. P. Leist, G. Comi, B. Cree, P. K. Coyle, M. S. Freedman et al., Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial, Lancet Neurol. mars, vol.13, issue.3, pp.257-67, 2014.

S. Cook, P. Vermersch, G. Comi, G. Giovannoni, K. Rammohan et al., Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study, Mult Scler Houndmills Basingstoke Engl. mai, vol.17, issue.5, pp.578-93, 2011.

D. Wynn, M. Kaufman, X. Montalban, T. Vollmer, J. Simon et al., Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta, Lancet Neurol. avr, vol.9, issue.4, pp.381-90, 2010.

R. Gold, G. Giovannoni, K. Selmaj, E. Havrdova, X. Montalban et al., Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial, Lancet Lond Engl. 22 juin, vol.381, issue.9884, pp.2167-75, 2013.
DOI : 10.1016/s0140-6736(12)62190-4

L. Kappos, H. Wiendl, K. Selmaj, D. L. Arnold, E. Havrdova et al., Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.373, issue.15, pp.1418-1446, 2015.

G. Giovannoni, R. Gold, K. Selmaj, E. Havrdova, X. Montalban et al., Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial, Lancet Neurol. mai, vol.13, issue.5, pp.472-81, 2014.

H. L. Atkins, M. Bowman, D. Allan, G. Anstee, D. L. Arnold et al., Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial, Lancet Lond Engl. 6 août, vol.388, pp.576-85, 2016.

A. Bar-or, L. Fawaz, B. Fan, P. J. Darlington, A. Rieger et al., Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?, Ann Neurol. avr, vol.67, issue.4, pp.452-61, 2010.

R. Li, A. Rezk, Y. Miyazaki, E. Hilgenberg, H. Touil et al., Proinflammatory GM-CSFproducing B cells in multiple sclerosis and B cell depletion therapy, Sci Transl Med, vol.7, issue.310, pp.310-166, 2015.

S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel et al., B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis, N Engl J Med. 14 févr, vol.358, issue.7, pp.676-88, 2008.

R. T. Naismith, L. Piccio, J. A. Lyons, J. Lauber, N. T. Tutlam et al., Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial, Neurology. 8 juin, vol.74, issue.23, pp.1860-1867, 2010.

J. Salzer, R. Svenningsson, P. Alping, L. Novakova, A. Björck et al., Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy, Neurology, vol.87, issue.20, pp.2074-81, 2016.

H. Tony, G. Burmester, H. Schulze-koops, M. Grunke, J. Henes et al., Safety and clinical outcomes of Rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID), Arthritis Res Ther. 13 mai, vol.13, issue.3, p.75, 2011.

. Graid-investigators, P. S. Rommer, T. Dörner, K. Freivogel, J. Haas et al., Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID), J Neuroimmune Pharmacol. mars, vol.11, issue.1, pp.1-8, 2016.

P. S. Sorensen, S. Lisby, R. Grove, F. Derosier, S. Shackelford et al., Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study, Neurology. 18 févr, vol.82, issue.7, pp.573-81, 2014.

A. Bar-or, P. Calabresi, D. Arnold, D. Arnlod, C. Markowitz et al., Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial, Ann Neurol. mars, vol.63, issue.3, pp.395-400, 2008.

L. Kappos, D. Li, P. A. Calabresi, O. Connor, P. Bar-or et al., Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, Lancet Lond Engl, vol.378, issue.9805, pp.1779-87, 2011.

S. L. Hauser, A. Bar-or, G. Comi, G. Giovannoni, H. Hartung et al., Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.19, issue.3, pp.221-255, 2017.

P. Alping, T. Frisell, L. Novakova, P. Islam-jakobsson, J. Salzer et al., Rituximab versus fingolimod after natalizumab in multiple sclerosis patients: Rituximab vs Fingolimod, Ann Neurol. juin, vol.79, issue.6, pp.950-958, 2016.

T. Spelman, T. Frisell, F. Piehl, and J. Hillert, Comparative effectiveness of Rituximab relative to IFN-? or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry, Mult Scler Houndmills Basingstoke Engl. 1 juin, p.1352458517713668, 2017.

E. Pucci, G. Giuliani, A. Solari, S. Simi, S. Minozzi et al., Natalizumab for relapsing remitting multiple sclerosis, Cochrane Database Syst Rev, issue.10, p.7621, 2011.

H. Butzkueven, L. Kappos, F. Pellegrini, M. Trojano, H. Wiendl et al., Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results, J Neurol Neurosurg Psychiatry, vol.85, issue.11, pp.1190-1197, 2014.

H. Hartung, R. Gonsette, N. König, H. Kwiecinski, A. Guseo et al., Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet Lond Engl. 21 déc, vol.360, issue.9350, pp.2018-2043, 2002.

F. A. Van-de-wyngaert, C. Beguin, D. 'hooghe, M. B. Dooms, G. Lissoir et al., A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis, Acta Neurol Belg. déc, vol.101, issue.4, pp.210-216, 2001.

R. F. Van-vollenhoven, R. M. Fleischmann, D. E. Furst, S. Lacey, and P. B. Lehane, Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11

, Years. J Rheumatol, vol.42, issue.10, pp.1761-1767, 2015.

B. Huggett, Public biotech 2012-the numbers, Nat Biotechnol. 8 août, vol.31, issue.8, pp.697-703, 2013.